APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting Insulin Injection

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Long-acting Insulin Injection Market Outlook and Growth Opportunities 2026

23 December 2025208 pages

Choose your research edition.

Industry ResearchLong-acting Insulin Injection Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting Insulin Injection Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Long-acting Insulin Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting Insulin Injection Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting Insulin Injection Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Long-acting Insulin Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Long-acting Insulin Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Long-acting Insulin Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long-acting Insulin Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Long-acting Insulin Injection market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Long-acting Insulin Injection market include United Laboratories, Tonghua Dongbao, Sanofi, Novo Nordisk, Eli Lilly & Co, Gan & Lee, Wockhardt, Viatris and Swixx Biopharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Long-acting Insulin Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Long-acting Insulin Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Long-acting Insulin Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Long-acting Insulin Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Long-acting Insulin Injection Segment by Company

United Laboratories

Tonghua Dongbao

Sanofi

Novo Nordisk

Eli Lilly & Co

Gan & Lee

Wockhardt

Viatris

Swixx Biopharma

Lupin Laboratories

KALBE PHARMA

INFION PHARMA

Cipla

Biocon Biologics

Biocare

Abbott Laboratories

Long-acting Insulin Injection Segment by Type

Insulin Glargine

Insulin Detemir

Insulin Degludec

Long-acting Insulin Injection Segment by Application

Type 1 Diabetes

Type 2 Diabetes

Long-acting Insulin Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Long-acting Insulin Injection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Long-acting Insulin Injection market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Long-acting Insulin Injection significant trends, drivers, influence factors in global and regions.

6. To analyze Long-acting Insulin Injection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Insulin Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting Insulin Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Insulin Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Long-acting Insulin Injection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Long-acting Insulin Injection industry.

Chapter 3: Detailed analysis of Long-acting Insulin Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Long-acting Insulin Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Long-acting Insulin Injection in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Long-acting Insulin Injection Industry Trends Table 2. Long-acting Insulin Injection Industry Drivers Table 3. Long-acting Insulin Injection Industry Opportunities and Challenges Table 4. Long-acting Insulin Injection Industry Restraints Table 5. Global Long-acting Insulin Injection Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Long-acting Insulin Injection Revenue Share by Company (2021-2026) Table 7. Global Long-acting Insulin Injection Sales Volume by Company (k units) & (2021-2026) Table 8. Global Long-acting Insulin Injection Sales Volume Share by Company (2021-2026) Table 9. Global Long-acting Insulin Injection Average Price (USD/unit) of Company (2021-2026) Table 10. Global Long-acting Insulin Injection Company Ranking, (2024-2026) & (USD Million) Table 11. Global Long-acting Insulin Injection Key Company Manufacturing Base & Headquarters Table 12. Global Long-acting Insulin Injection Company, Product Type & Application Table 13. Global Long-acting Insulin Injection Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Long-acting Insulin Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Insulin Glargine Table 18. Significant Companies of Insulin Detemir Table 19. Significant Companies of Insulin Degludec Table 20. Global Long-acting Insulin Injection Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Long-acting Insulin Injection Sales Volume by Type (2021-2026) & (k units) Table 22. Global Long-acting Insulin Injection Sales Volume by Type (2027-2032) & (k units) Table 23. Global Long-acting Insulin Injection Sales Volume Share by Type (2021-2026) Table 24. Global Long-acting Insulin Injection Sales Volume Share by Type (2027-2032) Table 25. Global Long-acting Insulin Injection Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Long-acting Insulin Injection Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Long-acting Insulin Injection Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Long-acting Insulin Injection Sales Value Share by Type (2021-2026) Table 29. Global Long-acting Insulin Injection Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Type 1 Diabetes Table 31. Significant Companies of Type 2 Diabetes Table 32. Global Long-acting Insulin Injection Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Long-acting Insulin Injection Sales Volume by Application (2021-2026) & (k units) Table 34. Global Long-acting Insulin Injection Sales Volume by Application (2027-2032) & (k units) Table 35. Global Long-acting Insulin Injection Sales Volume Share by Application (2021-2026) Table 36. Global Long-acting Insulin Injection Sales Volume Share by Application (2027-2032) Table 37. Global Long-acting Insulin Injection Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Long-acting Insulin Injection Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Long-acting Insulin Injection Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Long-acting Insulin Injection Sales Value Share by Application (2021-2026) Table 41. Global Long-acting Insulin Injection Sales Value Share by Application (2027-2032) Table 42. Global Long-acting Insulin Injection Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Long-acting Insulin Injection Sales by Region (2021-2026) & (k units) Table 44. Global Long-acting Insulin Injection Sales Market Share by Region (2021-2026) Table 45. Global Long-acting Insulin Injection Sales by Region (2027-2032) & (k units) Table 46. Global Long-acting Insulin Injection Sales Market Share by Region (2027-2032) Table 47. Global Long-acting Insulin Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Long-acting Insulin Injection Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Long-acting Insulin Injection Sales Value Share by Region (2021-2026) Table 50. Global Long-acting Insulin Injection Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Long-acting Insulin Injection Sales Value Share by Region (2027-2032) Table 52. Global Long-acting Insulin Injection Market Average Price (USD/unit) by Region (2021-2026) Table 53. Global Long-acting Insulin Injection Market Average Price (USD/unit) by Region (2027-2032) Table 54. Global Long-acting Insulin Injection Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Long-acting Insulin Injection Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Long-acting Insulin Injection Sales by Country (2021-2026) & (k units) Table 57. Global Long-acting Insulin Injection Sales Market Share by Country (2021-2026) Table 58. Global Long-acting Insulin Injection Sales by Country (2027-2032) & (k units) Table 59. Global Long-acting Insulin Injection Sales Market Share by Country (2027-2032) Table 60. Global Long-acting Insulin Injection Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Long-acting Insulin Injection Sales Value Market Share by Country (2021-2026) Table 62. Global Long-acting Insulin Injection Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Long-acting Insulin Injection Sales Value Market Share by Country (2027-2032) Table 64. United Laboratories Company Information Table 65. United Laboratories Business Overview Table 66. United Laboratories Long-acting Insulin Injection Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 67. United Laboratories Long-acting Insulin Injection Product Portfolio Table 68. United Laboratories Recent Development Table 69. Tonghua Dongbao Company Information Table 70. Tonghua Dongbao Business Overview Table 71. Tonghua Dongbao Long-acting Insulin Injection Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 72. Tonghua Dongbao Long-acting Insulin Injection Product Portfolio Table 73. Tonghua Dongbao Recent Development Table 74. Sanofi Company Information Table 75. Sanofi Business Overview Table 76. Sanofi Long-acting Insulin Injection Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 77. Sanofi Long-acting Insulin Injection Product Portfolio Table 78. Sanofi Recent Development Table 79. Novo Nordisk Company Information Table 80. Novo Nordisk Business Overview Table 81. Novo Nordisk Long-acting Insulin Injection Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 82. Novo Nordisk Long-acting Insulin Injection Product Portfolio Table 83. Novo Nordisk Recent Development Table 84. Eli Lilly & Co Company Information Table 85. Eli Lilly & Co Business Overview Table 86. Eli Lilly & Co Long-acting Insulin Injection Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 87. Eli Lilly & Co Long-acting Insulin Injection Product Portfolio Table 88. Eli Lilly & Co Recent Development Table 89. Gan & Lee Company Information Table 90. Gan & Lee Business Overview Table 91. Gan & Lee Long-acting Insulin Injection Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Gan & Lee Long-acting Insulin Injection Product Portfolio Table 93. Gan & Lee Recent Development Table 94. Wockhardt Company Information Table 95. Wockhardt Business Overview Table 96. Wockhardt Long-acting Insulin Injection Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Wockhardt Long-acting Insulin Injection Product Portfolio Table 98. Wockhardt Recent Development Table 99. Viatris Company Information Table 100. Viatris Business Overview Table 101. Viatris Long-acting Insulin Injection Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. Viatris Long-acting Insulin Injection Product Portfolio Table 103. Viatris Recent Development Table 104. Swixx Biopharma Company Information Table 105. Swixx Biopharma Business Overview Table 106. Swixx Biopharma Long-acting Insulin Injection Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. Swixx Biopharma Long-acting Insulin Injection Product Portfolio Table 108. Swixx Biopharma Recent Development Table 109. Lupin Laboratories Company Information Table 110. Lupin Laboratories Business Overview Table 111. Lupin Laboratories Long-acting Insulin Injection Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. Lupin Laboratories Long-acting Insulin Injection Product Portfolio Table 113. Lupin Laboratories Recent Development Table 114. KALBE PHARMA Company Information Table 115. KALBE PHARMA Business Overview Table 116. KALBE PHARMA Long-acting Insulin Injection Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 117. KALBE PHARMA Long-acting Insulin Injection Product Portfolio Table 118. KALBE PHARMA Recent Development Table 119. INFION PHARMA Company Information Table 120. INFION PHARMA Business Overview Table 121. INFION PHARMA Long-acting Insulin Injection Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 122. INFION PHARMA Long-acting Insulin Injection Product Portfolio Table 123. INFION PHARMA Recent Development Table 124. Cipla Company Information Table 125. Cipla Business Overview Table 126. Cipla Long-acting Insulin Injection Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 127. Cipla Long-acting Insulin Injection Product Portfolio Table 128. Cipla Recent Development Table 129. Biocon Biologics Company Information Table 130. Biocon Biologics Business Overview Table 131. Biocon Biologics Long-acting Insulin Injection Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 132. Biocon Biologics Long-acting Insulin Injection Product Portfolio Table 133. Biocon Biologics Recent Development Table 134. Biocare Company Information Table 135. Biocare Business Overview Table 136. Biocare Long-acting Insulin Injection Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 137. Biocare Long-acting Insulin Injection Product Portfolio Table 138. Biocare Recent Development Table 139. Abbott Laboratories Company Information Table 140. Abbott Laboratories Business Overview Table 141. Abbott Laboratories Long-acting Insulin Injection Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 142. Abbott Laboratories Long-acting Insulin Injection Product Portfolio Table 143. Abbott Laboratories Recent Development Table 144. Key Raw Materials Table 145. Raw Materials Key Suppliers Table 146. Long-acting Insulin Injection Distributors List Table 147. Long-acting Insulin Injection Customers List Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. Long-acting Insulin Injection Product Image Figure 2. Global Long-acting Insulin Injection Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting Insulin Injection Sales Value (2021-2032) & (US$ Million) Figure 4. Global Long-acting Insulin Injection Sales (2021-2032) & (k units) Figure 5. Global Long-acting Insulin Injection Sales Average Price (USD/unit) & (2021-2032) Figure 6. Global Long-acting Insulin Injection Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Insulin Glargine Image Figure 10. Insulin Detemir Image Figure 11. Insulin Degludec Image Figure 12. Global Long-acting Insulin Injection Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Long-acting Insulin Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Long-acting Insulin Injection Sales Volume Share by Type (2021-2032) Figure 15. Global Long-acting Insulin Injection Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Long-acting Insulin Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Long-acting Insulin Injection Sales Value Share by Type (2021-2032) Figure 18. Type 1 Diabetes Image Figure 19. Type 2 Diabetes Image Figure 20. Global Long-acting Insulin Injection Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Long-acting Insulin Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Long-acting Insulin Injection Sales Volume Share by Application (2021-2032) Figure 23. Global Long-acting Insulin Injection Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Long-acting Insulin Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Long-acting Insulin Injection Sales Value Share by Application (2021-2032) Figure 26. Global Long-acting Insulin Injection Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Long-acting Insulin Injection Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Long-acting Insulin Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Long-acting Insulin Injection Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Long-acting Insulin Injection Sales Value (2021-2032) & (US$ Million) Figure 31. North America Long-acting Insulin Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Long-acting Insulin Injection Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Long-acting Insulin Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Long-acting Insulin Injection Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Long-acting Insulin Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Long-acting Insulin Injection Sales Value (2021-2032) & (US$ Million) Figure 37. South America Long-acting Insulin Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Long-acting Insulin Injection Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Long-acting Insulin Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Long-acting Insulin Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Long-acting Insulin Injection Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Long-acting Insulin Injection Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Insulin Glargine
  • Insulin Detemir
  • Insulin Degludec
Applications
  • Type 1 Diabetes
  • Type 2 Diabetes
Companies covered
  • United Laboratories
  • Tonghua Dongbao
  • Sanofi
  • Novo Nordisk
  • Eli Lilly & Co
  • Gan & Lee
  • Wockhardt
  • Viatris
  • Swixx Biopharma
  • Lupin Laboratories
  • KALBE PHARMA
  • INFION PHARMA
  • Cipla
  • Biocon Biologics
  • Biocare
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Long-acting Insulin Injection Sales Value (2021-2032)
  4. 1.2.2 Global Long-acting Insulin Injection Sales Volume (2021-2032)
  5. 1.2.3 Global Long-acting Insulin Injection Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Long-acting Insulin Injection Market Dynamics
  1. 2.1 Long-acting Insulin Injection Industry Trends
  2. 2.2 Long-acting Insulin Injection Industry Drivers
  3. 2.3 Long-acting Insulin Injection Industry Opportunities and Challenges
  4. 2.4 Long-acting Insulin Injection Industry Restraints
3 Long-acting Insulin Injection Market by Company
  1. 3.1 Global Long-acting Insulin Injection Company Revenue Ranking in 2025
  2. 3.2 Global Long-acting Insulin Injection Revenue by Company (2021-2026)
  3. 3.3 Global Long-acting Insulin Injection Sales Volume by Company (2021-2026)
  4. 3.4 Global Long-acting Insulin Injection Average Price by Company (2021-2026)
  5. 3.5 Global Long-acting Insulin Injection Company Ranking (2024-2026)
  6. 3.6 Global Long-acting Insulin Injection Company Manufacturing Base and Headquarters
  7. 3.7 Global Long-acting Insulin Injection Company Product Type and Application
  8. 3.8 Global Long-acting Insulin Injection Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Long-acting Insulin Injection Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Long-acting Insulin Injection Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Long-acting Insulin Injection Market by Type
  1. 4.1 Long-acting Insulin Injection Type Introduction
  2. 4.1.1 Insulin Glargine
  3. 4.1.2 Insulin Detemir
  4. 4.1.3 Insulin Degludec
  5. 4.2 Global Long-acting Insulin Injection Sales Volume by Type
  6. 4.2.1 Global Long-acting Insulin Injection Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Long-acting Insulin Injection Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Long-acting Insulin Injection Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Long-acting Insulin Injection Sales Value by Type
  10. 4.3.1 Global Long-acting Insulin Injection Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Long-acting Insulin Injection Sales Value by Type (2021-2032)
  12. 4.3.3 Global Long-acting Insulin Injection Sales Value Share by Type (2021-2032)
5 Long-acting Insulin Injection Market by Application
  1. 5.1 Long-acting Insulin Injection Application Introduction
  2. 5.1.1 Type 1 Diabetes
  3. 5.1.2 Type 2 Diabetes
  4. 5.2 Global Long-acting Insulin Injection Sales Volume by Application
  5. 5.2.1 Global Long-acting Insulin Injection Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Long-acting Insulin Injection Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Long-acting Insulin Injection Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Long-acting Insulin Injection Sales Value by Application
  9. 5.3.1 Global Long-acting Insulin Injection Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Long-acting Insulin Injection Sales Value by Application (2021-2032)
  11. 5.3.3 Global Long-acting Insulin Injection Sales Value Share by Application (2021-2032)
6 Long-acting Insulin Injection Regional Sales and Value Analysis
  1. 6.1 Global Long-acting Insulin Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Long-acting Insulin Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Long-acting Insulin Injection Sales by Region: 2021-2026
  4. 6.2.2 Global Long-acting Insulin Injection Sales by Region (2027-2032)
  5. 6.3 Global Long-acting Insulin Injection Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Long-acting Insulin Injection Sales Value by Region (2021-2032)
  7. 6.4.1 Global Long-acting Insulin Injection Sales Value by Region: 2021-2026
  8. 6.4.2 Global Long-acting Insulin Injection Sales Value by Region (2027-2032)
  9. 6.5 Global Long-acting Insulin Injection Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Long-acting Insulin Injection Sales Value (2021-2032)
  12. 6.6.2 North America Long-acting Insulin Injection Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Long-acting Insulin Injection Sales Value (2021-2032)
  15. 6.7.2 Europe Long-acting Insulin Injection Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Long-acting Insulin Injection Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Long-acting Insulin Injection Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Long-acting Insulin Injection Sales Value (2021-2032)
  21. 6.9.2 South America Long-acting Insulin Injection Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Long-acting Insulin Injection Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Long-acting Insulin Injection Sales Value Share by Country, 2025 VS 2032
7 Long-acting Insulin Injection Country-level Sales and Value Analysis
  1. 7.1 Global Long-acting Insulin Injection Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Long-acting Insulin Injection Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Long-acting Insulin Injection Sales by Country (2021-2032)
  4. 7.3.1 Global Long-acting Insulin Injection Sales by Country (2021-2026)
  5. 7.3.2 Global Long-acting Insulin Injection Sales by Country (2027-2032)
  6. 7.4 Global Long-acting Insulin Injection Sales Value by Country (2021-2032)
  7. 7.4.1 Global Long-acting Insulin Injection Sales Value by Country (2021-2026)
  8. 7.4.2 Global Long-acting Insulin Injection Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Long-acting Insulin Injection Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Long-acting Insulin Injection Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Long-acting Insulin Injection Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 United Laboratories
  2. 8.1.1 United Laboratories Company Information
  3. 8.1.2 United Laboratories Business Overview
  4. 8.1.3 United Laboratories Long-acting Insulin Injection Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 United Laboratories Long-acting Insulin Injection Product Portfolio
  6. 8.1.5 United Laboratories Recent Developments
  7. 8.2 Tonghua Dongbao
  8. 8.2.1 Tonghua Dongbao Company Information
  9. 8.2.2 Tonghua Dongbao Business Overview
  10. 8.2.3 Tonghua Dongbao Long-acting Insulin Injection Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Tonghua Dongbao Long-acting Insulin Injection Product Portfolio
  12. 8.2.5 Tonghua Dongbao Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Long-acting Insulin Injection Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Long-acting Insulin Injection Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Novo Nordisk
  20. 8.4.1 Novo Nordisk Company Information
  21. 8.4.2 Novo Nordisk Business Overview
  22. 8.4.3 Novo Nordisk Long-acting Insulin Injection Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novo Nordisk Long-acting Insulin Injection Product Portfolio
  24. 8.4.5 Novo Nordisk Recent Developments
  25. 8.5 Eli Lilly & Co
  26. 8.5.1 Eli Lilly & Co Company Information
  27. 8.5.2 Eli Lilly & Co Business Overview
  28. 8.5.3 Eli Lilly & Co Long-acting Insulin Injection Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly & Co Long-acting Insulin Injection Product Portfolio
  30. 8.5.5 Eli Lilly & Co Recent Developments
  31. 8.6 Gan & Lee
  32. 8.6.1 Gan & Lee Company Information
  33. 8.6.2 Gan & Lee Business Overview
  34. 8.6.3 Gan & Lee Long-acting Insulin Injection Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Gan & Lee Long-acting Insulin Injection Product Portfolio
  36. 8.6.5 Gan & Lee Recent Developments
  37. 8.7 Wockhardt
  38. 8.7.1 Wockhardt Company Information
  39. 8.7.2 Wockhardt Business Overview
  40. 8.7.3 Wockhardt Long-acting Insulin Injection Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Wockhardt Long-acting Insulin Injection Product Portfolio
  42. 8.7.5 Wockhardt Recent Developments
  43. 8.8 Viatris
  44. 8.8.1 Viatris Company Information
  45. 8.8.2 Viatris Business Overview
  46. 8.8.3 Viatris Long-acting Insulin Injection Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Viatris Long-acting Insulin Injection Product Portfolio
  48. 8.8.5 Viatris Recent Developments
  49. 8.9 Swixx Biopharma
  50. 8.9.1 Swixx Biopharma Company Information
  51. 8.9.2 Swixx Biopharma Business Overview
  52. 8.9.3 Swixx Biopharma Long-acting Insulin Injection Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Swixx Biopharma Long-acting Insulin Injection Product Portfolio
  54. 8.9.5 Swixx Biopharma Recent Developments
  55. 8.10 Lupin Laboratories
  56. 8.10.1 Lupin Laboratories Company Information
  57. 8.10.2 Lupin Laboratories Business Overview
  58. 8.10.3 Lupin Laboratories Long-acting Insulin Injection Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Lupin Laboratories Long-acting Insulin Injection Product Portfolio
  60. 8.10.5 Lupin Laboratories Recent Developments
  61. 8.11 KALBE PHARMA
  62. 8.11.1 KALBE PHARMA Company Information
  63. 8.11.2 KALBE PHARMA Business Overview
  64. 8.11.3 KALBE PHARMA Long-acting Insulin Injection Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 KALBE PHARMA Long-acting Insulin Injection Product Portfolio
  66. 8.11.5 KALBE PHARMA Recent Developments
  67. 8.12 INFION PHARMA
  68. 8.12.1 INFION PHARMA Company Information
  69. 8.12.2 INFION PHARMA Business Overview
  70. 8.12.3 INFION PHARMA Long-acting Insulin Injection Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 INFION PHARMA Long-acting Insulin Injection Product Portfolio
  72. 8.12.5 INFION PHARMA Recent Developments
  73. 8.13 Cipla
  74. 8.13.1 Cipla Company Information
  75. 8.13.2 Cipla Business Overview
  76. 8.13.3 Cipla Long-acting Insulin Injection Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Cipla Long-acting Insulin Injection Product Portfolio
  78. 8.13.5 Cipla Recent Developments
  79. 8.14 Biocon Biologics
  80. 8.14.1 Biocon Biologics Company Information
  81. 8.14.2 Biocon Biologics Business Overview
  82. 8.14.3 Biocon Biologics Long-acting Insulin Injection Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Biocon Biologics Long-acting Insulin Injection Product Portfolio
  84. 8.14.5 Biocon Biologics Recent Developments
  85. 8.15 Biocare
  86. 8.15.1 Biocare Company Information
  87. 8.15.2 Biocare Business Overview
  88. 8.15.3 Biocare Long-acting Insulin Injection Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Biocare Long-acting Insulin Injection Product Portfolio
  90. 8.15.5 Biocare Recent Developments
  91. 8.16 Abbott Laboratories
  92. 8.16.1 Abbott Laboratories Company Information
  93. 8.16.2 Abbott Laboratories Business Overview
  94. 8.16.3 Abbott Laboratories Long-acting Insulin Injection Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Abbott Laboratories Long-acting Insulin Injection Product Portfolio
  96. 8.16.5 Abbott Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Long-acting Insulin Injection Value Chain Analysis
  2. 9.1.1 Long-acting Insulin Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Long-acting Insulin Injection Sales Mode & Process
  6. 9.2 Long-acting Insulin Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Long-acting Insulin Injection Distributors
  9. 9.2.3 Long-acting Insulin Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst